Introduction {#s1}
============

Zinc finger nuclease (ZFN) is an artificial restriction enzyme that causes DNA double-strand breaks (DSB) on a specific locus of genome sequences, and is useful for genome editing by error-prone non-homologous-end-joining (NHEJ) or homologous recombination with exogenous DNA [@pone.0059801-Durai1], [@pone.0059801-Porteus1]. ZFN is reported to function in various cells including embryos and to be able to generate vertebrates, plants and insects with specific genetic modifications [@pone.0059801-PerezPinera1]--[@pone.0059801-Bibikova1].

ZFNs consist of C2H2 zinc finger (ZF) domains and a FokI-derived DNA endonuclease domain. Paired ZFNs bind to the plus and minus strands of the target locus with 5--6 bp gaps [@pone.0059801-Maeder1] and digest DNA by dimerized nucleases [@pone.0059801-Miller1]. A ZF domain binds to a specific DNA triplet through its 7-amino-acid DNA-recognition helix and a different combination of 7 amino acids will bind to a different DNA triplet. By combining multiple ZF domains with different recognition helices, ZFNs are able to bind specifically to arbitrarily chosen DNA target sites [@pone.0059801-Carroll1], [@pone.0059801-Mackay1]. The relationship between the amino acid sequence of the DNA recognition helix and the target DNA triplets has been widely investigated [@pone.0059801-Maeder1], [@pone.0059801-Carroll1]--[@pone.0059801-Gupta1], and website tools for designing the appropriate ZF against endogenous DNA sequences have been developed [@pone.0059801-Mandell1]--[@pone.0059801-Cradick1] However, the lack of activity against endogenous target sites have been recently pointed out in ZFNs designed by these webstites. It is difficult to design an exclusive ZFN, which functions with selectivity at each unique target site. Therefore, it is beneficial to be able to design several ZFN pairs against several sites within one target gene. This makes developing an easy and efficient ZFN construction method very important.

At present, two major construction methods are being commonly used: one is the overlapping of synthetic long oligonucleotides by PCR [@pone.0059801-Carroll1] and the other is the assembly of ZF modules from a prepared ZF-coding plasmid DNA library through consecutive restriction and ligation reactions [@pone.0059801-Wright1], [@pone.0059801-Gonzalez1]. In the former method, an approximately 300 bp DNA sequence coding 3 ZF DNA-binding domains is divided into several synthetic long (a few dozen bp) oligonucleotide fragments, which have overlap sequences with the adjacent fragments in both ends, and these fragments are combined by PCR using the overlap sequences. Carroll et al. formulated a method to construct ZFNs consisting of 3 ZFs by overlapping 4 or more synthetic long oligonucleotides (60 bp\<). They reported that the design, construction and cloning could be completed within about two weeks if all steps went smoothly, and expression and testing could be completed in an additional week [@pone.0059801-Carroll1]. Osborn et al. improved this method to shorten the construction period from design to testing to 1 week by constructing a specific expression vector consisting of nucleases and bound it with the prepared ZFs by enzymatic recombination [@pone.0059801-Osborn1]. However, the number of ZFs in each array was confined to 3 (ZF1, ZF2 and ZF3) in these reports, and the overlap sequences of ZF1, ZF2 and ZF3 were selected from different sites of the ZF domain in order to combine them into the correct order at once with PCR. In other words, an oligonucleotide containing the DNA-recognition helix of ZF1 could not be used for a different position, i.e. ZF2 or ZF3, and as a result, renewed multiple long oligonucleotides were required for constructing a new ZF in a different position even if its DNA-recognition helix is the same. In another method called ZF modular assembly, the desired ZF module is cut out from the ZF-module-library vector by a restriction enzyme, and the ZF module is connected sequentially one by one. In this method, all ZF modules can be used interchangeably, however, consecutive restriction and ligation reactions are complex and time consuming. As an alternative to self-construction methods, ready-made or custom-made ZFNs can be purchased commercially, but doing so is costly and requires a long time [@pone.0059801-Defrancesco1]. Due to the above reasons, the previously reported ZFN-preparation methods have both merits and demerits in terms of cost, time, labour, and repeatability. Therefore, the establishment of a novel inexpensive, rapid and simple method for ZFN construction may be necessary for ZFN technology to reach its full potential.

In the present study, we attempted to establish a novel ZFN construction method. As different parts of various ZFs were confined within the DNA recognition helix, we designed short PCR primers (\<30 bp) corresponding to the helix to try to synthesize each ZF by PCR, and combined 4--6 ZFs by overlap extension PCR. Furthermore, in order to connect these PCR-derived ZFs and nuclease vector rapidly by TA cloning without the use of restriction enzymes, a nuclease-coding platform vector which could be used as a TA vector for ZFN construction was designed and synthesized. For this [o]{.ul}ver[l]{.ul}ap extension PCR and [TA]{.ul}-cloning method, which we named "OLTA", we designed and constructed 4 sets of ZFN vectors against 2 reported loci, *Rosa26* [@pone.0059801-PerezPinera2] and Interleukin 2 receptor, gamma chain (*Il2rg*) [@pone.0059801-Mashimo1], and 2 original loci, GLI-Kruppel family member GLI3 (*Gli3*) and cyclin-dependent kinase inhibitor 1B (*Cdkn1b*), each within a single day and finished until the *E. coli* transformation process, or within three days including the colony selection and the sequencing procedure of the ZFN vectors. Moreover, the functions of the constructed ZFNs were evaluated by injecting them into the mouse embryos, and site-directed mutagenesis of endogenous target loci was examined. Then, we attempted to generate a genetically modified mouse using a set of synthesized ZFNs.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

All animal care and experiments conformed to the Guidelines for Animal Experiments of The University of Tokyo, and were approved by the Animal Research Committee of The University of Tokyo.

Construction of Platform Vectors {#s2b}
--------------------------------

The platform-vector construct is shown in [Figure 1A](#pone-0059801-g001){ref-type="fig"}. A ZFN cassette consisting of the SV40 nuclear-localization sequence, the flanking sequence of the C2H2 zinc finger containing restriction sites of PvuII and BstZ17I, and the FokI-derived nuclease domain including KK or EL obligate heterodimer mutations [@pone.0059801-Miller1] and the Sharkey mutation [@pone.0059801-Guo1] were constructed from 12 synthetic oligonucleotides by overlap extension PCR using a thermal cycler. The ZFN cassette was digested by BglII and KpnI and was inserted into the BglII-KpnI site of a pCMV-Tag1 vector. Next, the 3′ UTR of mouse TATA box binding protein-like 1 with a 95-bp polyadenine tail, which was cloned from adult mouse testis cDNA according to previous report [@pone.0059801-Salls1], was inserted into the KpnI site of the above vector in order to induce constitutive high expression. The vector was digested with DraII and AflIII to eliminate unnecessary restriction sites, and joined with a DraII-AflIII-digested pUC19 fragment coding the ampicillin resistance gene. Then, the constructed vector was sequenced using a commercial sequencing kit (Applied Biosystems, Foster City, CA) and a DNA sequencer (Applied Biosystems) according to the manufacturer's instructions, and is referred to hereafter as the "platform vector". The sequence of the platform vector is shown in [Figure S1](#pone.0059801.s001){ref-type="supplementary-material"}. Before TA cloning, the platform vector was digested with PvuII and BstZ17I, and ddTTP was added to the 3′ end of digested sites using terminal transferase. The treated platform vector was purified by agarose gel electrophoresis, extracted using a gel extraction kit, and stored at −20°C until use.

![Experimental schemes for vector construction.\
(A) Composition of the platform vector used for ZFN construction. (B) Construction procedures for ZFN vectors by OLTA. In this figure, construction of a DNA-binding domain composed of 4 ZFs is shown as an example. Three partial ZF fragments were synthesized by the 1st PCR with the primer sets shown in [Table 2](#pone-0059801-t002){ref-type="table"} and they were combined by overlap extension PCR (2nd PCR) and amplified by 3rd PCR; then the DNA-binding domain was joined with the platform vector by TA cloning. (C) A scheme showing constructs of *in vitro* transcribed ZFN mRNA and *in vivo* translated ZFN protein, and ZFN binding with target DNA; *Gli3* target site is shown in this figure for example.](pone.0059801.g001){#pone-0059801-g001}

Construction of ZF-template Vector {#s2c}
----------------------------------

The zinc finger domain of mouse early-growth-response protein 1 (*Egr1*) has been well studied of its function and configuration [@pone.0059801-ElrodErickson1]--[@pone.0059801-Wolfe2], and has been used for ZFN in previous reports [@pone.0059801-Carroll1], [@pone.0059801-Osborn1]. In the present study, the partial sequence (104 bp) from the first to the second DNA recognition helices of *Egr1* ZF domain (1327--1431 of NM_007913) was cloned from adult mouse testis (cDNA by RT-PCR) using the appropriate forward primer (5′-CGCTCGGATGCGCTTACCCGCCATATCCG-3′) and reverse primer (5′-CGGGCAAGATTATCCGAGCGACTGAAG-3′). The PCR product was cloned into a pGEM-T Easy vector, and is referred to here as the "ZF template vector". The ZF template vector was sequenced as described above, and the sequence of the inserted ZF domain is shown in [Figure S2](#pone.0059801.s002){ref-type="supplementary-material"}.

Construction of ZFN Vector by Overlap Extension PCR and TA-cloning (OLTA) {#s2d}
-------------------------------------------------------------------------

Target sequence and DNA-recognition helices of ZFN against *Rosa26* were the same as those reported previously [@pone.0059801-PerezPinera2], and those against *Il2rg* were drawn from the report in rat [@pone.0059801-Mashimo1] with a change of ZF2 DNA-recognition helices in the left-ZFN from TAG to GCG according to the mouse sequence (GCA GCG TGA GGT TGG). Target sites of *Gli3* and *Cdkn1b* were determined by searching the GNN triplet or reported high quality triplet [@pone.0059801-Carroll1] from their sequences. These target sequences were shown in [Table 1](#pone-0059801-t001){ref-type="table"}, and an outline of ZFN vector construction is shown in [Figure 1B](#pone-0059801-g001){ref-type="fig"}. All PCR were performed using the primer sets shown in [Table 2](#pone-0059801-t002){ref-type="table"} on the condition of [Table 3](#pone-0059801-t003){ref-type="table"}. The 3rd PCR products were cloned into the PvuII/BstZ17I digested and 3′-T-added platform vectors by TA-cloning. The left-side ZFs and the right-side ZFs were cloned into the KK platform vector and the EL platform vector, respectively, referred to hereafter as the left-ZFN vector and right-ZFN vector, respectively. After transformation of competent cells with these vectors and plating on LB plates, the colonies were subjected to colony PCR using T3-promoter primer as a forward primer and the reverse primer of 3rd PCR to confirm the correct insertion and direction of PCR products. The vectors that have the correct insertion size with true direction of PCR product were sequenced as described above.

10.1371/journal.pone.0059801.t001

###### ZFN target sequences and ZF alignment of each ZFN.

![](pone.0059801.t001){#pone-0059801-t001-1}

  Gene        Target Sequence             ZF1             ZF2   ZF3   ZF4   ZF5   ZF6  
  ---------- ----------------- ------------------------- ----- ----- ----- ----- ----- -----
  *Gli3*           Left             GAG CTG TGG GCC       GCC   TGG   CTG   GAG        
                   Right            GAC TGA GAG GAA       GAA   GAG   TGA   GAC        
                                                                                       
  *Rosa26*         Left         AGA AAG ACT GGA GTT GCA   GCA   GTT   GGA   ACT   AAG   AGA
                   Right            TGG GCG GGA GTC       GTC   GGA   GCG   TGG        
                                                                                       
  *Il2rg*          Left           GCA GCG TGA GGT TGG     TGG   GGT   TGA   GCG   GCA  
                   Right          GGT ATG AGA AGG GGG     GGG   AGG   AGA   ATG   GGT  
                                                                                       
  *Cdkn1b*         Left             GCG GGT GTG GAC       GAC   GTG   GGT   GCG        
                   Right            GAG GAA GAT GTC       GTC   GAT   GAA   GAG        

10.1371/journal.pone.0059801.t002

###### Primer sets for 1st PCR.

![](pone.0059801.t002){#pone-0059801-t002-2}

  Target DNA triplet    DNA-recognition-helix sequence   Forward Primer[\*](#nt101){ref-type="table-fn"} (NDN)[\*\*](#nt102){ref-type="table-fn"}   Reverse Primer[\*](#nt101){ref-type="table-fn"} (NDN)[\*\*](#nt102){ref-type="table-fn"}        
  -------------------- -------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ ----- ------------------------------------
  GAA                              QSGNLAR                                                         5′-                                                                         CaaTCGGgTaacCTTgCCCGCCATATCCG (7)                               5′-   GGCGGGCAAGgTTAcCCGAttGACTGAAG (4)
  GAC                              DRSNLTR                                                         5′-                                                                         gaCagGagTaatCTTACCCGCCATATCCG (9)                               5′-   GGCGGGtAAGATTActCcTGtcACTGAAG (6)
  GAG                              RSDNLAR                                                         5′-                                                                         CGCTCGGATaatCTTgCCCGCCATATCCG (4)                               5′-   GGCGGGCAAGATTATCCGAGCGACTGAAG (0)
  GAT                              TSGNLVR                                                         5′-                                                                         acCTCGGgTaatCTTgtCCGCCATATCCG (8)                               5′-   GGCGGaCAAGATTAcCCGAGgaACTGAAG (4)
  GCA                              QSGDLTR                                                         5′-                                                                         CaaTCGGgTGatCTTACCCGCCATATCCG (5)                               5′-   GGCGGGtAAGATcAcCCGAttGACTGAAG (4)
  GCC                              DCRDLAR                                                         5′-                                                                         gaCTGcagaGacCTTgCCCGCCATATCCG (9)                               5′-   GGCGGGCAAGgTctctgcAGtaACTGAAG (9)
  GCG                              RSDDLQR                                                         5′-                                                                         CGCTCGGATGacCTTcaaCGCCATATCCG (5)                               5′-   GGCGttgAAGgTcATCCGAGCGACTGAAG (5)
  GGA                              QSGHLQR                                                         5′-                                                                         CagTCGGgTcatCTTcaaCGCCATATCCG (9)                               5′-   GGCGttgAAGATgAcCCGActGACTGAAG (7)
  GGG                              RSDHLSR                                                         5′-                                                                         CGCTCGGATcacCTTtCCCGCCATATCCG (4)                               5′-   GGCGGGaAAGgTgATCCGAGCGACTGAAG (3)
  GGT                              TSGHLVR                                                         5′-                                                                         acCTCGGgTcacCTTgtCCGCCATATCCG (8)                               5′-   GGCGGaCAAGgTgAcCCGAGgtACTGAAG (6)
  GTC                              DPGALVR                                                         5′-                                                                         gaCcCGGgTGCGCTTgtCCGCCATATCCG (6)                               5′-   GGCGGaCAAGcgcAtCCGgGtcACTGAAG (8)
  GTG                              RSDALTR                                                         5′-                                                                         CGCTCGGATGCGCTTACCCGCCATATCCG (0)                               5′-   GGCGGGtAAGcgcATCCGAGCGACTGAAG (4)
  GTT                              TSGSLVR                                                         5′-                                                                         acCTCGGgTtCGtTagtCaGaCATATCCG (10)                              5′-   GtCtGaCtAacgaATCCGAGgtACTGAAG (10)
  AAG                              RKDNLKN                                                         5′-                                                                         CGCaaGGATaacCTTAaaaaCCATATCCG (9)                               5′-   GGtttttAAGgTTATCCttGCGACTGAAG (8)
  ACT                              THLDLIR                                                         5′-                                                                         acCcacctTGatCTTAtCCGCCATATCCG (10)                              5′-   GGCGGatAAGATcAaggtgGgtACTGAAG (10)
  AGA                              QLAHLRA                                                         5′-                                                                         CaaTtGGcTcacCTTcgCgcCCATATCCG (11)                              5′-   GGgcGcgAAGgTgAgCCaAttGACTGAAG (10)
  AGG                              RSDHLTN                                                         5′-                                                                         CGCTCGGATcacCTTACCaaCCATATCCG (5)                               5′-   GGttGGtAAGgTgATCCGAGCGACTGAAG (5)
  ATG                              RRDELNV                                                         5′-                                                                         CGCcgGGATGaGCTTAACgtCCATATCCG (5)                               5′-   GGacGttAAGcTcATCCcgGCGACTGAAG (8)
  CTG                              RNDALTE                                                         5′-                                                                         CGCaatGAcGCGCTTACCgaaCATATCCG (7)                               5′-   GttcGGtAAGcgcgTCattGCGACTGAAG (11)
  TGA                              QAGHLAS                                                         5′-                                                                         CaagCGGgTcatCTTgCCaGCCATATCCG (9)                               5′-   GGCtGGCAAGATgAcCCGcttGACTGAAG (6)
  TGG                              RSDHLTT                                                         5′-                                                                         CGCagtGATcacCTTACCacCCATATCCG (8)                               5′-   GGgtGGtAAGgTgATCactGCGACTGAAG (8)

The capital letters and small letters show same and different nucleotides compared to the zinc-finger-template vector.

Number of different nucleotides compared to the zinc-finger-template vector.

10.1371/journal.pone.0059801.t003

###### Overlap-extension PCR conditions.

![](pone.0059801.t003){#pone-0059801-t003-3}

  PCR mixture                                                                                              PCR conditions  
  ------------------------------------------------------------------------------------------------------- ---------------- -------------
  **1st PCR**                                                                                                              
   5 µl of 10X Ex Taq Buffer                                                                                95°C, 2 min    
   4 µl of dNTP Mixture (2.5 mM each)                                                                       95°C, 15 sec    X 40 cycles
   2.5 µl of 10 µM Forward primer                                                                           54°C, 15 sec   
   2.5 µl of 10 µM Reverse primer                                                                           72°C, 15 sec   
   1 µl of 100 µg/ml Template vector                                                                        72°C, 5 min    
   0.5 µl of 5 U/µl Ex Taq                                                                                                 
   34.5 µl of Ultra pure water                                                                                             
  **2nd PCR**                                                                                                              
   5 µl of 10X Ex Taq Buffer                                                                                95°C, 2 min    
   4 µl of dNTP Mixture (2.5 mM each)                                                                       94°C, 30 sec    X 15 cycles
   0.5 µl of 5 U/µl Ex Taq                                                                                  68°C, 30 sec   
   1st PCR amplicons (10 µg/ml each)                                                                        68°C, 5 min    
   0.5 µl each of ZF1-ZF2 and ZF3-ZF4 amplicons and 1.5 µl of ZF2-3 amplicon (4ZF)                                         
   or 0.5 µl each of ZF1-ZF2 and ZF4-ZF5 amplicons and 1.5 µl each of ZF2-3 and ZF3-4 amplicons (5ZF)                      
   or 0.5 µl each of ZF1-ZF2, ZF2-ZF3, ZF4-ZF5 and ZF5-ZF6 amplicons and 1.5 µl of ZF3-4 amplicon (6ZF)                    
   Adjust to 50 µl with Ultra pure water                                                                                   
  **3rd PCR**                                                                                                              
   5 µl of 10X Ex Taq Buffer                                                                                95°C, 2 min    
   4 µl of dNTP Mixture (2.5 mM each)                                                                       94°C, 30 sec    X 25 cycles
   2.5 µl of 10 µM ZF1 Forward primer                                                                       68°C, 30 sec   
   2.5 µl of 10 µM ZF4 (4ZF), ZF5 (5ZF) or ZF6 (6ZF) Reverse primer                                         68°C, 5 min    
   0.5--1 µl of 2nd PCR reacted mixture                                                                                    
   0.5 µl of 5 U/µl Ex Taq                                                                                                 
   Adjust to 50 µl with Ultra pure water                                                                                   

*In vitro* Synthesis of mRNA {#s2e}
----------------------------

For the *in vitro* synthesis of mRNAs, constructed left-ZFN and right-ZFN vectors were linearized by XhoI and transcribed *in vitro* with T3-RNA-polymerase (Promega) in the presence of m7G(5′)ppp(5′)G to synthesize capped RNA transcripts. The RNA transcripts were precipitated with absolute ethanol, washed and resuspended in RNase-free water (GIBCO). The mRNA concentration was adjusted to 20 µg/ml or 200 µg/ml and the left- and right-ZFN mRNAs were mixed as 1∶1. The RNA solutions were stored at −80°C until use.

Microinjection of mRNA into Zygote {#s2f}
----------------------------------

Following the guidelines for animal experiments at The University of Tokyo, sexually immature female C57BL/6NCr mice (4--5 weeks olds) were superovulated by intraperitoneal injection of 7.5 IU eCG followed by 7.5 IU hCG at an interval of 48 h, and mated overnight with C57BL/6NCr male mice that were more than 10 weeks old. Zygotes were collected after 20 h of hCG injection by oviductal flashing, and pronuclei-formed zygotes were put into the M2 medium. Microinjection was performed using microinjector (Narishige) equipped with microscope. Approximately 4 pl of RNA solution were injected into the cytoplasm of each zygote by continuous pneumatic pressure. After injection, all zygotes were cultured in M16 medium for 24 h and subjected for following experiments.

Genomic PCR of Single Embryo {#s2g}
----------------------------

For genome DNA collection, an individual 2-cell embryo was put in 10 µl of Ex Taq buffer (RR001B, TaKaRa), digested with 1 µg/µl of Proteinase K at 60°C for 30 min and heat-inactivated at 95°C for 10 min. The embryo lysate solutions were subjected to PCR on the condition of [Table 4](#pone-0059801-t004){ref-type="table"} using the primer sets in [Table 5](#pone-0059801-t005){ref-type="table"}. The PCR products were purified by agarose gel electrophoresis, then extracted and sequenced as described above.

10.1371/journal.pone.0059801.t004

###### Genomic PCR conditions.

![](pone.0059801.t004){#pone-0059801-t004-4}

  PCR mixture                                            Reaction conditions  
  ----------------------------------------------------- --------------------- -----------------------------------------------------------
  2 µl of 10X Ex Taq Buffer                                  95°C, 5 min      
  2.4 µl of dNTP Mixture (2.5 mM each)                      94°C, 30 sec       X 40 cycles for 2-cell embryo or X 35 cycles for tale DNA
  1.5 µl of 10 µM Forward primer                            57°C, 30 sec      
  1.5 µl of 10 µM Reverse primer                            72°C, 40 sec      
  10 µl of embryo lysate or 1 µl of tale DNA solution        72°C, 5 min      
  0.6 µl of 5 U/ml Ex Taq                                                     
  12 µl of UltraPure Water                                                    

10.1371/journal.pone.0059801.t005

###### Primer sets for genomic PCR.

![](pone.0059801.t005){#pone-0059801-t005-5}

  Target gene    Primor sequence        
  ------------- ----------------- ----- ---------------------------
  *Rosa26*           Forward       5′-     ACGTTTCCGACTTGAGTTGC
                     Reverse       5′-      ATACTCCGAGGCGGATCAC
                                        
  *Gli3*             Forward       5′-   GTTACTTAAGGGACGTGAAAACTCA
                     Reverse       5′-   ACTAAAGTCTGCCCACCCTATACAC
                                        
  *Il2rg*            Forward       5′-   ATGACTAAAACGAAGTGTGCAGAG
                     Reverse       5′-   TAGAGAAGGGTTACAAGGCAAAAG
                                        
  *Cdkn1b*           Forward       5′-    TCCAGTACACTTGATCACTGAAG
                     Reverse       5′-    CCTGTAGTAGAACTCGGGCAAG

Immunoblotting {#s2h}
--------------

The micro-western blotting was used for the immunoblotting of the zygotes as described in a previous report [@pone.0059801-Naito1]. Forty zygotes injected with 200 µg/ml mRNA solutions were used in each lane. The antibodies used were anti-Flag M2 monoclonal antibody (F1804, Sigma-Aldrich) and anti-α tubulin monoclonal antibody (T5168, Sigma-Aldrich). To visualize the protein-bound antibodies, horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Jackson ImmunoReserch Laboratories, Inc., West Grove, PA) was used as a second layer, followed by detection procedure using an ECL detection kit (Amersham-Pharmacia) according to the manufacture's protocol.

Immunocytochemistry {#s2i}
-------------------

After 4 h of mRNA injection, zygotes were fixed in 3.7% paraformaldehyde and permeabilized in 0.2% triton X-100. These zygotes were treated with anti-Flag M2 monoclonal antibody (F1804, Sigma-Aldrich) overnight. After washing, the zygotes were incubated in fluorescein-isothiocyanate (FITC)-conjugated anti-mouse IgG (55494, MP Biomedicals) for 60 min. DNA was visualized by propidium iodide staining, and then examined under a confocal laser scanning microscope (LSM510-V2.01, Axioplan MOT; Carl Zeiss, Oberkochen, Germany).

T7 Endonuclease I Assay {#s2j}
-----------------------

Genome DNAs were obtained from ten 2-cell embryos injected with 20 µg/ml mRNA solutions as described above, and subjected to PCR using the primer sets shown in [Table 3](#pone-0059801-t003){ref-type="table"}. The purified PCR products were incubated at 95°C for 10 min, then cooled to 85°C at −2°C/sec and to 25°C at −0.5°C/sec for annealing of intact and mutated DNA strands. The re-annealed products were incubated with 2 U of T7 endonuclease I at 37°C for 3 h, then subjected to agarose gel electrophoresis.

Embryo Transfer and Genotyping of Pups {#s2k}
--------------------------------------

Two-cell embryos injected with 20 µg/ml ZFN mRNA solutions were transferred into the oviductal ampullas (10--17 embryos per oviduct) of 8-week-old female ICR mouse mated the previous night by vasectomized ICR males. After birth, approximately 1 mm of tail tips were obtained from the 4-day-old pups. Genome DNA was extracted from the tail tips and subjected to PCR on the condition of [Table 4](#pone-0059801-t004){ref-type="table"} using the primers shown in [Table 5](#pone-0059801-t005){ref-type="table"}. PCR products were purified by agarose gel electrophoresis, and the extracted fragments were directly sequenced as described above.

Results {#s3}
=======

Construction of ZFNs by OLTA {#s3a}
----------------------------

At first, we examined whether the intended ZF could be produced efficiently by overlap PCR utilizing DNA-recognition helices as overlap regions. Short PCR primers consisting of a 21-bp DNA-recognition helix reported previously [@pone.0059801-Carroll1] and an 8-bp ZF common region were designed ([Table 2](#pone-0059801-t002){ref-type="table"}) and partial ZF fragments extending from the DNA-recognition helix to the next DNA-recognition helix, were synthesized by 1st PCR using ZF-template vector and a forward primer (Fw) of one DNA-recognition helix and a reverse primer (Rv) of the next DNA-recognition helix. For the production of *Gli3* left-ZFN, for example, GCC-Fw and TGG-Rv, TGG-Fw and CTG-Rv, and CTG-Fw and GAG-Rv were used as primer sets and 3 partial ZF fragments of ZF1-ZF2, ZF2-ZF3 and ZF3-ZF4 were synthesized. As shown in [Figure 2A](#pone-0059801-g002){ref-type="fig"} 1st PCR, all partial ZF fragments were successfully synthesized from the PCR primer sets shown in [Table 2](#pone-0059801-t002){ref-type="table"}. The 1st PCR products were purified by agarose gel electrophoresis and extracted, and then the 3--5 partial ZF fragments (equivalent to 4--6 ZFs) were subjected to a 2nd PCR without a PCR primer (overlap extension PCR) in order to elongate the PCR products. A 3rd PCR was performed using diluted whole 2nd PCR products without purification and extraction, and PCR primers for both ends, for example GCC-Fw and GAG-Rv for *Gli3* left-ZFN. Although no obvious band was observed from the 2nd PCR products ([Figure 2A](#pone-0059801-g002){ref-type="fig"}, 2nd PCR), the electrophoresis of the 3rd PCR products showed ladder bands including one at the intended molecular weight ([Figure 2A](#pone-0059801-g002){ref-type="fig"}, 3rd PCR). The putative intended molecules extracted from the correct bands of the gels were ligated with platform vectors by TA-cloning; then the ligated vectors were mixed with competent cells and plated. These processes were competed within one day as shown in [Table 6](#pone-0059801-t006){ref-type="table"}. On the following day, colony PCR was performed using T3-promoter primer as forward primer and the reverse primer of 3rd PCR, and each four colonies showing the correct molecular weight and correct direction were selected from each plate. As shown in Figuer 2B, 1 to 4 of the 4 colonies had the intended ZF sequences after sequencing without any reference to the number of ZFs in each array. These results show that the vectors of ZFNs composed of 4--6 ZFs can be produced efficiently by the combination of overlap PCR, utilizing DNA-recognition helices as overlap regions, and TA-cloning. *In vitro* transcribed mRNAs of each ZFN set were injected into mouse zygotes, and the protein expressions of ZFN were observed by western blotting at the correct molecular weight ([Figure 2C](#pone-0059801-g002){ref-type="fig"}) and by immunocytochemistry in the pronuclei at 4 h after microinjection ([Figure 2D](#pone-0059801-g002){ref-type="fig"}), indicating that the ZFN protein could stably exist in the nucleus in the zygote stage.

![The construction and expression of ZFNs.\
(A) Three-step PCR for the construction of DNA-binding domain of ZFs. PCR products for each PCR step for 6-finger ZF (left-ZF of *Rosa26*), 5-finger ZF (left-ZF of *Il2rg*), and 4-finger ZF (left-ZF of *Gli3*) are shown. Arrows indicate the intended base pairs of PCR products. (B) Construction efficiencies of left- and right-ZFNs for 4 target loci. (C, D) The expression of constructed ZFN in mouse zygotes. ZFN mRNA at 200 µg/ml (100 µg/ml each for right- and left-ZFNs) were injected into the cytoplasm of mouse zygotes and after 4 h, ZFN protein expression was confirmed by immunoblotting (C) and immunocytochemistry (D) with anti-Flag antibody. Alpha-tubulin immunoblotting is shown as the internal control, and DNA was stained by propidium iodide.](pone.0059801.g002){#pone-0059801-g002}

10.1371/journal.pone.0059801.t006

###### Time schedule for OLTA.

![](pone.0059801.t006){#pone-0059801-t006-6}

  Procedure                                 Time required (h)
  ------------------------------- --------------------------------------
  Day 1                           
  1st PCR                                           1
  Gel purification                                  1
  2nd PCR                                          \] 1
  3rd PCR                         
  Gel purification                                 1.5
  Ligation                                        0.5--1
  Transformation, Plating                          0.5
  Day 2                           
  Colony PCR                                        2
  Gel electrophorasis                               1
  Culture of candidate colonies    O/N[\*](#nt103){ref-type="table-fn"}
  Day 3                           
  Plasmid DNA isolation                             1
  Sequencing reaction                               6

Overnight.

Functional Analysis of the Constructed ZFNs {#s3b}
-------------------------------------------

In order to evaluate the site-directed nuclease activity of the constructed ZFNs, ZFN mRNA sets against four different genome loci, *Rosa26*, *Gli3*, *Il2rg* and *Cdkn1b*, were injected into zygotes and the induction of mutations on the target loci were observed after 24 h of injection. First, PCR for the target loci was performed using 10 embryos, and the PCR products were denatured, re-annealed and treated with T7 endonuclease I, which digests the mismatched base pair. As a result, short fragments caused by mismatch digestion were observed in the ZFN mRNA-injected groups of all target loci ([Figure 3](#pone-0059801-g003){ref-type="fig"}), suggesting the digestion of the target loci by the constructed ZFNs. Then, these PCR products were directly sequenced using each forward primer. Microinjection of 200 µg/ml ZFN mRNA against *Gli3* and *Rosa26* resulted in target-site mutations in higher efficiency than microinjection of 20 µg/ml ZFN mRNA ([Table 7](#pone-0059801-t007){ref-type="table"}), however even in the case of 20 µg/ml ZFN mRNA injection, mutated embryos were present at target loci for all ZFNs ([Table 7](#pone-0059801-t007){ref-type="table"}). These results indicate that all of the constructed ZFNs could function as site-directed endonucleases.

![Functional analysis of the constructed ZFNs in preimplantation mouse embryos.\
Each of ten 2-cell embryos injected with 20 µg/ml of ZFN mRNAs (10 µg/ml each for right- and left-ZFNs) were subjected to T7 endonuclease I assay. Arrows indicate the mismatch-digestion fragments derived from ZFN-induced genome mutation at the target loci. The other fragments digested at the provable SNP sites are indicated by arrowheads.](pone.0059801.g003){#pone-0059801-g003}

10.1371/journal.pone.0059801.t007

###### ZFN-induced site-directed mutations in mouse 2-cell embryos.

![](pone.0059801.t007){#pone-0059801-t007-7}

  Target gene    ZFN concentration (µg/ml)   No. of embryos   Sequence of target site[\*](#nt104){ref-type="table-fn"}   Modification (S, D, I)[\*\*](#nt105){ref-type="table-fn"}   Number of embryos  
  ------------- --------------------------- ---------------- ---------------------------------------------------------- ----------------------------------------------------------- ------------------- ----
  *Gli3*                    200                    16                                    3                                    A[GGCCCACAGCTC]{.ul}TACGGC[GACTGAGAGGAA]{.ul}G                WT           13
                                                                                                                                     AGCCCCACAGCTCTtCGGCGACTGAGAGGAAG                       1 S          1
                                                                                                                                      AGGCCCCCAGCTCT--GCGACTGAGAGGAAG                       3 D          1
                                                                                                                                          AG--------------------                           142 D         1
                            20                     32                                    3                                    A[GGCCCACAGCTC]{.ul}TACGGC[GACTGAGAGGAA]{.ul}G                WT           29
                                                                                                                                     AGGCCCACAGCTCT-CGGCGACTGAGAGGAAG                       1 D          1
                                                                                                                                       AGG-----------GACTGAGAGGAAAG                         16D          1
                                                                                                                                      AGGCCCACAGtTtT--GCGACTGAGAGGAAG                    3 D, 2 S        1
  *Rosa26*                  200                    9                                     9                                 C[TGCAACTCCAGTCTTTCT]{.ul}AGAAGA[TGGGCGGGAGTC]{.ul}T             WT           0
                                                                                                                                   CTGCAACTCCAGTCTTTCTAGA--TGGGCGGGAGTCT                    3 D          4
                                                                                                                                    CTGCAACTCCAG--------ATGGtCGGGAGTCT                     12 D          1
                                                                                                                                     CTGCAACTCCAGGCTTTCTA-----------CT                     16 D          1
                                                                                                                                      CTGCAACTCCAG----------------TCT                      23 D          1
                                                                                                                                       CTGCAAC---------------------                        122 D         1
                                                                                                                                        ----------------------AGTCT                        146 D         1
                            20                     31                                    5                                 C[TGCAACTCCAGTCTTTCT]{.ul}AGAAGA[TGGGCGGGAGTC]{.ul}T             WT           26
                                                                                                                                  CTGCAACTCCAGTCTTTCTAGAA--TGGGCGGGAGTCT                    2 D          1
                                                                                                                                   CTGCAACTCCAGTCTTTCTAGAA--GGGCGGGAGTCT                    3 D          1
                                                                                                                                   CTGCAACTCCAGTCTTTCTAGA--TGGGCGGGAGTCT                    3 D          2
                                                                                                                                   CTGCAACTCCAGTCTTT-----ATGGGCGGGAGTCT                     7 D          1
  *Il2rg*                   20                     30                                    4                                 A[CCAACCTCACGCTGC]{.ul}ACTATA[GGTATGAGAAGGGGG]{.ul}A             WT           26
                                                                                                                                   ACCAACCTCACGCTGCAC--AGGTATGAGAAGGGGGA                    3 D          1
                                                                                                                                   ACCAACCTCACGCTGCAC---GGTATGAGAAGGGGGA                    4 D          1
                                                                                                                                    ACCAACCTCACGCTGCA------TGAGAAGGGGGA                     9 D          1
                                                                                                                                  ACCCACCTCACGCTCCAtcacaaccttttgcctGGGGA                   16 I          1
  *Cdkn1b*                  20                     39                                    3                                     G[GTCCACACCCGC]{.ul}CCGAG[GAGGAAGATGTC]{.ul}A                WT           36
                                                                                                                                      GGTCCACACCCGCCC-AGGAGGAAGATGTCA                       1 D          1
                                                                                                                                      GGTCCACACCCGCC--AGGAGGAAGATGTCA                       2 D          1
                                                                                                                                      GGTCCACACCCaCCgGAGGAGGAAGATGTCA                       2 S          1

Under lines indicate the target sites of ZFNs. Small letters and hyphen show the different and deleted nucleotides compared to the WT sequences, respectively.

S: substitution, D: deletion, I: insertion.

Generation of Site-directed Mutated mice Using the Constructed ZFN {#s3c}
------------------------------------------------------------------

Finally, we examined the toxicity of constructed ZFNs and whether the constructed ZFN vectors were useful for the generation of site-directed mutated mice. About 80% of the embryos injected with water or 20 µg/ml of *Gli3*, *Rosa26* or *Il2rg* ZFN mRNA developed to become blastocysts (Table8). However, the embryos injected with *Cdkn1b* ZFN mRNA developed normally up to the 2-cell stage, but many of them stopped thereafter ([Table 8](#pone-0059801-t008){ref-type="table"}). Agreeing with these results, when the embryos injected with 20 µg/ml of ZFN mRNA were transferred into the oviducts of recipient mice at the 2-cell stage, site-directed mutated mice were obtained in every case other than *Cdkn1b* ZFN-mRNA injection ([Table 9](#pone-0059801-t009){ref-type="table"}), These results indicate that although *Cdkn1b* ZFN had some toxicities for embryo development, most of the ZFN vectors constructed by OLTA can be used for generation of site-directed mutated mice.

10.1371/journal.pone.0059801.t008

###### *In vitro* development of ZFN-injected mouse embryos.

![](pone.0059801.t008){#pone-0059801-t008-8}

  Target gene       No. (%) of embryos                        
  ---------------- -------------------- ----- --------- ----- ---------
  Non-injected              27           27    \(100\)   27    \(100\)
  Water-injected            40           38    \(95\)    32    \(80\)
  *Gli3*                   165           148   (89.7)    125   (75.8)
  *Rosa26*                  68           63    (92.6)    59    (86.8)
  *Il2rg*                   83           72    (86.7)    64    (77.1)
  *Cdkn1b*                  48           40    (83.3)    11    (22.9)

10.1371/journal.pone.0059801.t009

###### ZFN-induced site-directed mutations in new-born mouse.

![](pone.0059801.t009){#pone-0059801-t009-9}

  Target gene    2-cell embryos transferred   Born   Mutated   Sequence of terget site[\*](#nt106){ref-type="table-fn"}   Modification(D, I)[\*\*](#nt107){ref-type="table-fn"}   Number of embryos
  ------------- ---------------------------- ------ --------- ---------------------------------------------------------- ------------------------------------------------------- -------------------
  *Gli3*                     95                22       5        A[GGCCCACAGCTC]{.ul}TACGGC[GACTGAGAGGAA]{.ul}GAAAGC                               WT                                    17
                                                                 A[GGCCCACAGCTC]{.ul}T-CGGC[GACTGAGAGGAA]{.ul}GAAAGC                               1 D                                    1
                                                                 A[GGCCCACAGCTC]{.ul}TA-GGC[GACTGAGAGGAA]{.ul}GAAAGC                               1 D                                    1
                                                                 A[GGCCCACAGCTC]{.ul}TA--GC[GACTGAGAGGAA]{.ul}GAAAGC                               2 D                                    1
                                                                  A[GGCCCACAGCTC]{.ul}T----[GACTGAGAGGAA]{.ul}GAAAGC                               5 D                                    1
                                                                A[GGCCCACAGCTC]{.ul}TACGGggC[GACTGAGAGGAA]{.ul}GAAAGC                              2 I                                    1
  *Rosa26*                   42                7        1        C[TGCAACTCCAGTCTTTCT]{.ul}AGAAGA[TGGGCGGGAGTC]{.ul}T                              WT                                     6
                                                                 C[TGCAACTCCAGTCTTTCT]{.ul}A----[TGGGCGGGAGTC]{.ul}T                               5 D                                    1
  *Il2rg*                    40                8        1        A[CCAACCTCACGCTGC]{.ul}ACTATA[GGTATGAGAAGGGGG]{.ul}A                              WT                                     7
                                                                     A[CCAACCTCACGCTG-----GGTATGAGAAGGGGG]{.ul}A                                   7 D                                    1
  *Cdkn1b*                   61                0        0           G[GTCCACACCCGC]{.ul}CCGAG[GAGGAAGATGTC]{.ul}A                                  WT                                    \-

Under lines indicate the target sites of ZFNs. Small letters and hyphen show the inserted and deleted nucleotids compared to the WT seuences, respectively.

D: deletion, I: insertion.

Discussion {#s4}
==========

Although ZFN is a useful tool for site-directed genome modification, the development of useful construction methods that are easy, inexpensive and repeatedly usable for multiple kinds of ZFN should contribute to the further widespread use of this technology. In this study, we established a novel construction method named "OLTA", in which the intended DNA-binding domains, composed of 4 to 6 ZFs, were synthesized by overlap extension PCR of partial ZF fragments and joined with a nuclease vector by TA cloning. Using this method, we succeeded in constructing beneficial ZFN vectors in a low-cost manner in a short period of time. All ZFNs constructed by OLTA in the present study functioned as site-directed nucleases, and a genetically modified mouse was successfully generated using the constructed ZFN.

The most common construction method for ZFN thus far has been the assembly of ZF modules from a prepared ZF vector library [@pone.0059801-Wright1], [@pone.0059801-Gonzalez1] or the overlapping of synthetic long oligonucleotides by PCR [@pone.0059801-Carroll1], [@pone.0059801-Osborn1]. In the reported overlap-PCR method for ZFN construction, a DNA-binding domain of ZFN was divided into several synthetic long (60 bp\<) oligonucleotide fragments having overlap sequences in both ends, and these fragments were combined by PCR utilizing the overlap sequences. In this method, each DNA-recognition helix was coded at various positions in each fragment. In order to combine the multiple fragments into a correct order by PCR at once, the overlap sequences of each fragment were selected from different sites of ZF domain. Therefore an oligonucleotide coding one DNA-recognition helix could be used for only a specific position, and as a result, new long oligonucleotides were required each time for changing the ZF position. In contrast, OLTA amplifies common ZF framework by PCR using short (30 bp\>) primers consisting of a 21-bp DNA-recognition helix and an 8-bp ZF common region, and these partial ZF fragments extending from a DNA-recognition helix to the next DNA-recognition helix are combined by PCR utilizing the overlapped DNA-recognition helix sequences. Therefore, once prepared, the primers corresponding to each DNA triplet can be used repeatedly for the construction of other ZFN vectors without position limitation, in every case of the present study, partial ZF fragments were successfully synthesized precisely by the 1st PCR using each set of primers shown in [Table 2](#pone-0059801-t002){ref-type="table"} ([Figure 2A](#pone-0059801-g002){ref-type="fig"}). This result indicates that partial ZF fragments including various types of DNA recognition helices can be synthesized by the present PCR-primer conditions; the number of nucleotide differences with the template vector are 11 or less and 8 bp of 3′-end are completely complementary. Although only 21 kinds of DNA-recognition helices were synthesized in this study, more than 46 other kinds of DNA-recognition helices specific for various DNA triplets have been reported to date [@pone.0059801-Carroll1], [@pone.0059801-Mackay1]. All of these helices can be expected to be synthesized by OLTA, because their primer sets satisfy the above-mentioned PCR-primer conditions. Therefore, OLTA should be considered as a versatile and powerful method for ZFN construction.

It is highly conceivable that the numerical difference in ZFs have affected the ZFN recruiting efficiency for the correct position and mutation rates of endogenous target genome loci. The method of ZF-module assembly has the merit to combine ZFNs without number limitation at least in principle. However, this method requires consecutive restriction and ligation reactions, which make this method complex and time consuming. In contrast, ZFN vectors can be synthesized within a single day by OLTA; the construction process is completed within three days even if the transformation and the sequencing of ZFN vectors are included as shown in [Table 6](#pone-0059801-t006){ref-type="table"}. Furthermore, the fact that one month was sufficient for the generation of mice with site-directed mutations, from the construction of the ZFN to the obtaining of pups, indicates that an extremely short-term generation of genome-modified animals is possible with OLTA. With regard to the overlapping of long oligonucleotides, ZFNs can be synthesized in a short term as with OLTA [@pone.0059801-Osborn1], but the reported numbers of ZFs in DNA-binding domains have been confined to 3. The past routine for the preparation of a 6-finger protein, for example, was to make 3-finger proteins by overlap PCR and then to ligate the two 3-finger proteins together into a 6-finger protein. In the case of OLTA, at least 5 partial ZF fragments were successfully joined by 2nd and 3rd PCRs. The vector construction efficiencies, 1/4 to 4/4 (25--100%) in OLTA ([Figure 2B](#pone-0059801-g002){ref-type="fig"}), were almost the same as those (17--75%) reported previously. Thus, the OLTA method compensates adequately for the weak points of traditional construction methods.

In the present study, all four ZFN sets constructed by OLTA functioned as site-directed nucleases for genome DNA in mouse 2-cell embryos. The most likely explanation for the high ZFN activity on the endogenous target loci in the present study might be the presence of 4 to 6 ZFs in the present ZFN sets instead of 3 ZFs in the previous method. Previous reports studying the effects of ZF numbers on the target recognition efficiencies have shown enhancement of recognition efficiency by more than 4 ZFs [@pone.0059801-PerezPinera2], [@pone.0059801-Shimizu1], [@pone.0059801-Bhakta1]. Further, there are several reports about the direct-mutagenesis of mouse embryonic *Rosa26* locus using ZFN that have different numbers of fingers. Meyer et al generated site-directed mutated mice using ZFN sets that have 4- and 6-fingers for the target sequence the same as us, resulted that 22% of pups showed NHEJ-mediated mutation [@pone.0059801-Meyer1]. On the other hand, Hermann et al. reported that several 3-fingers of ZFN sets designed by OPEN generated only 0 to 7.4% of mutated pups [@pone.0059801-Hermann1]. In the present study, 4- and 6-finger ZFN sets against the *Rosa26* locus generated 14.3% of mutated pup ([Table 9](#pone-0059801-t009){ref-type="table"}), which efficiency is higher as well as Meyer's report than Hermann's. These results may support the hypothesis that the numbers of fingers increase the efficiencies of the mutation induction. Another reason might be the use of relatively high ZFN concentration for the evaluation of ZFN activities. It is well known that ZFNs have off-target effects, non-specific digestions of non-target sites, and this has become a general problem for ZFN experiments [@pone.0059801-Radecke1]. A previous report showed that off-target incidences increase depending on the concentration of ZFN [@pone.0059801-Pattanayak1]. The culture cells attacked by the off-target effects should be removed from the culture system by the induction of apoptosis even if their target loci were digested correctly. Therefore, the concentration of ZFNs was usually kept as low as possible to exert only the desired effect. On the other hand, we used mouse fertilized embryos that can develop to the 2-cell stage by the help of maternal factors even in the presence of off-target effects so as to evaluate the ZFN activity free of influence from off-target effects. In fact, although ZFNs injected at a concentration of 200 µg/ml showed higher mutation efficiency than those at 20 µg/ml, development stopped at the 2-cell stage and blastocysts were not observed. This failure of oocytes do develop further is most likely due to the off-target effect, by excessive ZFN expression.

The embryos injected with 20 µg/ml, all with the exception of *Cdkn1b*, ZFN mRNA successfully developed to pup that had mutations at the correct target loci. This result suggests that off-target effects can be evaded by using a 4 or more ZF-containing ZFN mRNA set at a concentration of 20 µg/ml. For the evasion of off-target toxicity of ZFN, another effective solution is thought to increase the number of ZFs in each array and elevating the ZFN specificity. Comparison study using human cells revealed that 3-finger-ZFNs showed off-target cutting at 31 loci whereas 4-finger-ZFNs showed 9 loci [@pone.0059801-Pattanayak1]. Until now, only 3 to 6 ZF-containing ZFNs have been used for site-directed genome modification, and the efficiency of more than 6 ZF-containing ZFNs has never been reported. One reason for this may have been the difficulty of constructing a long ZFN using conventional methods. In contrast, in the present electrophoretic patterns of the 3rd PCR, bands of longer than 6 ZF were observed ([Figure 2A](#pone-0059801-g002){ref-type="fig"}), suggesting that the OLTA method can be adopted for the construction of ZFNs consisting of more than 6 ZFs--although some DNA-binding domains obtained by OLTA in the present study showed incorrect ZF order. It is necessary to examine how many ZFs can be connected precisely by OLTA and confirm the correlation of ZF number to binding specificity and efficiency, in especially those greater than six.

In conclusion, the present study indicates that OLTA can be applied as a new ZFN construction method that is easy, non-expensive and available for repeated use for multiple kinds of ZFNs, thereby compensating for the weak points of the conventional methods. Recently, efficient construction methods for TAL-effecter nuclease, which is another artificial nuclease, have been reported [@pone.0059801-PerezPinera1]. Comparison of various kinds of ZFNs and TALENs constructed by various methods including OLTA is expected to contribute to the advancement of artificial nuclease technologies and genome-editing fields.
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